an internal medicine and pediatrics-trained allergist practicing in Mobile, Alabama.

Tapinarof Cream 1% Improves Sleep in Atopic Dermatitis, With Druhan Howell, MD

A post hoc pooled analysis of the phase 3 ADORING 1 and ADORING 2 trials suggests that once-daily tapinarof cream 1% is associated with early and sustained improvements in sleep-related outcomes in children aged 2 to 17 years with moderate to severe

 Improvements were observed as early as week 1 in some patients. In an interview with 

, Druhan Howell, MD, an allergist and immunologist in Mobile, Alabama, discussed how these findings may inform clinical conversations with families managing chronic disease.

“Week 1 [sleep] improvements are really meaningful for our patients,” Howell said. “Many of them who have shown up in the office have been dealing with atopic dermatitis and the unseen impacts of that for a long period of time, and so they are sleep-deprived. To get a good night's sleep after you haven't been sleeping is just kind of revolutionary.”

Tapinarof cream 1% (VTAMA) is a nonsteroidal topical aryl hydrocarbon receptor agonist approved by the US Food and Drug Administration (FDA) for the treatment of AD in patients aged ≥ 2 years and older.

 The ADORING 1 and ADORING 2 trials were identical, randomized, double-blind, vehicle-controlled phase 3 studies evaluating once-daily tapinarof for 8 weeks in pediatric patients with moderate to severe AD.

The newly reported sleep data derive from a pooled post hoc analysis of 654 tapinarof-treated children. Baseline disease burden was substantial, with mean Patient-Oriented Eczema Measure (POEM) scores ranging from 16.4 to 17.4, consistent with moderate to severe symptoms. Mean Dermatitis Family Impact (DFI) scores were between 7.7 and 9.1, reflecting moderate family burden.

At week 8, mean improvements in POEM sleep scores favored tapinarof over vehicle across all age cohorts: –1.9 vs –0.9 in children aged 2 to 6 years (

<.0001), –1.5 vs –1.0 in those aged 7 to 11 years (

 =.0029), and –1.2 vs –0.6 in adolescents aged 12 to 17 years (

 DFI sleep scores similarly demonstrated statistically significant improvements with tapinarof compared with vehicle: –1.1 vs –0.6 in children aged 2 to 6 years (

 =.0002), –0.6 versus –0.4 in those aged 7 to 11 years (P =.0049), and –0.4 versus –0.2 in adolescents aged 12 to 15 years (P =.0283).

Howell emphasized that although the primary endpoints of the ADORING trials focused on investigator-assessed skin clearance, the sleep findings capture a dimension of disease burden frequently highlighted in clinic but less often foregrounded in trial reporting. In her view, the ability to counsel families that measurable improvements in both itch and sleep may occur within the first week of therapy provides a concrete and clinically meaningful expectation.

The absolute differences in sleep score improvements between tapinarof and vehicle, although statistically significant, were modest. Whether these numeric changes correspond to clinically meaningful improvements at the individual level remains uncertain.

The consistency of improvement across pediatric age groups suggests that sleep and family impact may represent important adjunctive outcomes when evaluating therapeutic benefit in AD. As Howell described, incorporating sleep data into shared decision-making discussions may help contextualize treatment goals beyond lesion clearance alone, particularly in families coping with chronic nocturnal symptoms.

“I think all of us understand how important sleep is, and in our atopic dermatitis patients,” Howell said. “Disruption of sleep leads to problems…in children. That's behavior, that's [the] ability to function at school. This data [is] important because if we improve their sleep score, we can see those invisible burdens of atopic dermatitis improve for our patients and their families.”

Boguniewicz M, Eichenfield L, Kwong P, Hebert A. Improvement In Sleep And Family Impact For Pediatric Patients Down To 2 Years Of Age With Atopic Dermatitis Treated With Tapinarof Cream 1% Once Daily In Two Pivotal Phase 3 Trials. 

Journal of Allergy and Clinical Immunology

doi:https://doi.org/10.1016/j.jaci.2025.12.019

FDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older | Organon. Organon. Published January 20, 2025. 

https://www.organon.com/news/fda-approves-vtama-tapinarof-cream-1-for-the-treatment-of-atopic-dermatitis-in-adults-and-children-2-years-of-age-and-older/

Howell D. Tapinarof Shows Early, Sustained Benefits in Pediatric Atopic Dermatitis, With Druhan Howell, MD. HCPLive. Published on November 13, 2026. Accessed on February 27, 2026. 

https://www.hcplive.com/view/tapinarof-shows-early-sustained-benefits-in-pediatric-atopic-dermatitis-with-druhan-howell-md

Videos

Post hoc pooled data from ADORING 1 and 2 demonstrate statistically significant improvements in patient and family sleep scores in children aged 2–17 years

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Conference

 conference coverage page features articles, videos, and expert-led live coverage from major medical meetings throughout the year.

Atopic Dermatitis

Atopic Dermatitis condition center page, audiences can find a variety of coverage mediums for medical news and updates, including articles, video interviews, podcasts, and breaking news on dermatitis research, treatment, and drug development.

Sleep

On the HCPLive sleep page, resources on the topics of medical news and expert insight into sleep medicine can be found. Content includes articles, interviews, videos, podcasts, and breaking news on sleep apnea, insomnia, narcolepsy, and more.

CAFETERIA: Expanding Treatment Pathways for High-Threshold Peanut Allergy, with Scott Sicherer, MD

One year after the readout of the CAFETERIA trial, its implications for peanut allergy management continue to ripple through pediatric allergy practice. The NIH-sponsored study, published in 

, demonstrated that gradually increasing, home-measured doses of store-bought peanut butter over approximately 18 months enabled 100% of participating children with high-threshold peanut allergy to tolerate 9 grams of peanut protein, or the equivalent of 3 tablespoons of peanut butter, during supervised challenge.

 Even more striking, more than 2/3 achieved sustained unresponsiveness after a period of avoidance. For a population historically told that strict avoidance was their only option, the findings marked a meaningful shift.

Scott H. Sicherer, MD, Director of the Elliot and Roslyn Jaffe Food Allergy Institute and the Elliot and Roslyn Jaffe Professor of Pediatric Allergy and Immunology at the Icahn School of Medicine at Mount Sinai, gave a talk at the 

American Academy of Allergy, Asthma & Immunology (AAAAI)

 2026 Annual Meeting held in Philadelphia, Pennsylvania, on February 27-March 2, discussing the data and takeaways from the CAFETERIA study.

sat down with Sicherer at the meeting, who co-led the trial at the Elliot and Roslyn Jaffe Food Allergy Institute at Mount Sinai, to learn more about  CAFETERIA and its importance in addressing a long-overlooked gap in peanut allergy. Prior peanut immunotherapy trials focused primarily on children reactive to trace amounts, or those unable to tolerate even half a peanut. But roughly half of peanut-allergic children can already tolerate more than that threshold. For them, the question had long been: if they are already relatively protected against trace exposures, should clinicians simply advise continued avoidance?

Historically, the answer was yes. Children who reacted mildly at modest doses during an oral food challenge were typically labeled “still allergic” and sent home with instructions to avoid peanut entirely. CAFETERIA challenges that reflex. Sicherer noted that children with higher thresholds, often with lower peanut-specific IgE levels, proved highly responsive to a structured, low-cost oral immunotherapy approach using everyday products measured at home. The safety profile was favorable, and the success rate was high.

One year later, Sicherer says the study has reshaped his clinical thinking. Instead of defaulting to annual reassessment and continued avoidance, clinicians can now view high-threshold peanut allergy as a treatment opportunity.

“For those individuals who typically have lower IG levels, who might be ones that you'd want to do a feeding test for a food challenge, or discovering that they …don't react to the smallest amounts, is really a pathway, an opportunity to try to treat them. And so that's changed the thinking for us, and I hope for everyone,” Sicherer said.

Sicherer SH, Bunyavanich S, Berin MC, et al. Peanut Oral Immunotherapy in Children with High-Threshold Peanut Allergy. 

. Published online February 10, 2025. doi: 10.1056/evidoa2400306

Sicherer S. FAED Presents: The Potential for Tolerance After Oral Immunotherapy in High-Threshold Patients: The CAFETERIA Study. Presented at: AAAAI 2026 Annual Meeting, February 27-March 2, Philadelphia, Pennsylvania. Session 1705.

Sicherer discussed how findings from CAFETERIA may inform treatment decisions for children with high-threshold allergy.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

Tim Smith joined the MJH Life Sciences team in 2022 and is currently an associate editor for HCPLive. He is also the executive producer of two podcasts: Skin of Color Savvy and The Medical Sisterhood. Previously, he was the producer of the Lungcast podcast. He graduated from UC Berkeley and worked in multimedia journalism as a staff writer prior to joining MJH. You can contact him at tsmith@mjhlifesciences.com.

Treatment with nemolizumab (Nemluvio) for up to 3 years is linked with sustained disease control and a favorable tolerability profile among patients with 

These new findings were released February 27, 2026, by Galderma, resulting from the open-label extension phase of the OLYMPIA clinical program assessing nemolizumab in prurigo nodularis. The drug has been approved by the 

 for adults with prurigo nodularis and is now authorized in multiple countries for both prurigo nodularis and atopic dermatitis.

“Prurigo nodularis is not only intensely itchy, painful and uncomfortable, it can also take a profound toll on sleep, emotional wellbeing, and daily functioning,” Shawn Kwatra, MD, lead OLYMPIA investigator and Joseph W. Burnett Endowed Professor and Chairman of Dermatology at the University of Maryland School of Medicine, said in a statement.

 “That’s why achieving sustained, long-term disease control is critical for patients.”

Those with prurigo nodularis, a chronic neuroimmune-mediated dermatologic disease, often experience severe itch, the development of hyperkeratotic nodules, and significant sleep disturbances.

 In terms of prurigo nodularis’s prevalence, around 181,000 individuals in the US are believed to be impacted by the condition.

Nemolizumab was the first approved monoclonal antibody formulated to selectively inhibit the interleukin (IL)-31 receptor alpha, thereby blocking IL-31 signaling.

 This pathway is known to drive itch and related symptoms in those living with prurigo nodularis. Its efficacy and safety was evaluated in the OLYMPIA long-term extension study for up to 4 years.

508 of the participants in the earlier phase II study and the phase 3 OLYMPIA 1 and 2 studies were involved.

 At the 148-week mark, interim data among tthe patients evaluated in OLYMPIA demonstrated continued disease control with a safety profile consistent with prior results. Kwatra and colleagues found 70% of those involved attained clear or almost clear skin according to the Investigator’s Global Assessment (IGA), and over 85% reported greater than 75% lesion healing based on the prurigo activity score.

Clinically meaningful pruritus reductions were also observed in over 85% of participants, with approximately three-quarters attaining an itch-free or nearly itch-free state.

 Kwatra et al noted quality of life improvements among about 90% of subjects, with more than half achieving a Dermatology Life Quality Index (DLQI) score of 0 or 1. Such a score suggests no impact of the disease on quality of life. The study’s long-term safety data aligned with previously established data for nemolizumab in prurigo nodularis.

“These data show that [nemolizumab] can make a meaningful difference to people’s lives by improving itch, skin lesions and quality of life up to three years, with a well-tolerated safety profile,” Kwatra said in a statement.

Galderma’s release suggests these findings are scheduled for presentation at Winter Clinical Miami, expanding upon earlier results from OLYMPIA.

Galderma’s Nemluvio® (nemolizumab) demonstrates long-term disease control in prurigo nodularis up to three years. Galderma. February 27, 2026. 

https://www.galderma.com/news/galdermas-nemluvio-demonstrates-long-term-disease-control-prurigo-nodularis

Smith T. Nemolizumab Rapidly Relieves Itch in Atopic Dermatitis, Prurigo Nodularis. HCPLive. December 19, 2025. Accessed February 27, 2026. 

https://www.hcplive.com/view/nemolizumab-rapidly-relieves-itch-atopic-dermatitis-prurigo-nodularis

Articles

Nemolizumab, an anti–IL-31Rα monoclonal antibody, showed sustained long-term disease control and consistent tolerability in moderate-to-severe prurigo nodularis with treatment extending to roughly three years. In an open-label extension of the OLYMPIA program (interim analysis at 148 weeks), most patients achieved major improvements in skin clearance, lesion healing, pruritus, and quality of life. Approximately 70% reached clear or almost clear skin by IGA, with high rates of ≥75% lesion healing and clinically meaningful itch reduction, including near itch-free status for many.

These new data from the OLYMPIA open-label extension study highlight long-term safety and efficacy findings on nemolizumab (Nemluvio).

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

Nemolizumab Shows Long-Term Efficacy in Prurigo Nodularis for Up to 3 Years

Mohammad Anadani, MD, is the chief of neuroendovascular services for Intent Medical Group at the Endeavor Health Advanced Neurosciences Center.

Pregnancy-Related Maternal Stroke Increasing Across US, With Mohammad Anadani, MD

 incidence rates are steadily increasing in the US, increasing the mortality risk to both mother and child, according to a recent retrospective analysis.

Maternal stroke is notoriously understudied in recent years, with very limited data available since 2015. Prior studies have also included populations outside of the US, limiting the generalizability of results to US populations. Earlier studies have highlighted a rate of acute stroke of 45 per 100,000 hospitalizations – although this trend is not statistically significant, after transient ischemic attack (TIA) and unspecified codes were excluded, a substantial upward trend in incidence emerged.

“When we look at the US compared to other countries, we have a higher incidence of maternal stroke, and that incidence is, unfortunately, not going down,” Mohammad Anadani, MD, chief of neuroendovascular services for Intent Medical Group at the Endeavor Health Advanced Neurosciences Center, told 

 in an exclusive interview. “If we look at just stroke incidence rate in general, it is actually going down. I was hoping, when we did the study, to see the same trend in maternal stroke, but we need to make a lot more effort to try and decrease that incidence.”

Anadani and colleagues conducted a retrospective analysis using data sourced from the Epic Cosmos database, a multicenter data set incorporating deidentified electronic health record data from >300 million patient records from >1800 academic and private hospitals, as well as 41,500 clinics across all 50 US states. All pregnancies resulting in live births between January 1, 2016, and January 1, 2024, were included in the study.

Investigators defined maternal stroke as any inpatient encounter with a stroke-related diagnosis, including admission, discharge, or billing diagnosis, occurring from the start of pregnancy through 6 weeks postpartum. Stroke subtypes included ischemic stroke (IS), intracerebral hemorrhage, TIA, and subarachnoid hemorrhage.

The primary study outcome was the incidence of maternal stroke, focusing on trends over time for both overall and specific subtypes. Secondary outcomes were divided into maternal and neonatal, with maternal including mortality, discharge destination, and complications during delivery admission, while neonatal outcomes involved the 5-minute Apgar score, length of hospital stay, incidence of fetal and neonatal demise, and birth weight.

Ultimately, a total of 4,273,562 patients were enrolled in the study, accounting for 5,404,933 distinct pregnancies. Among these, 2637 were complicated by stroke. IS was the most common (52.6%), followed by hemorrhagic stroke (40.7% - 20% intracerebral and 20.7% subarachnoid). Investigators found that stroke was most frequent during the third trimester (51.3%) and the postpartum period (28.4%).

The rate of stroke per 100,000 pregnancies was 48.8, not reaching statistical significance. However, analysis by stroke type indicated an upward trend in IS, while others remained relatively stable. Investigators analyzed age trends and saw a substantial increase in the average age of patients throughout the study period. Generally, patients with stroke were older (31.1 vs 29.8 years; 

 <.001), more likely to be Black (31.3% vs 18.9%), and more likely to be smokers (14.9% vs 8.6%; 

Multivariable analysis highlighted several demographic and clinical factors independently associated with maternal stroke, including increasing maternal age (overall OR, 1.02; 95% CI, 1.01-1.03; ischemic OR, 1.02; 95% CI, 1.01-1.03; hemorrhagic OR, 1.05; 95% CI, 1.04-1.06). Congenital heart disease also showed strong association (overall OR, 5.74; 95% CI, 4.96-6.64), as did 

 (OR, 2.41; 95% CI, 1.91-3.03), and coronary artery disease (OR, 1.98; 95% CI, 1.52-2.58).

Ultimately, investigators concluded that the disparity in maternal stroke rates between the US and other high-income countries may be due to differences in risk factor profiles or health care access. The team highlights the need for effective management strategies, including strengthening surveillance, addressing underlying risk factors, and promoting preventive care.

“Recognition of stroke symptoms is very important, not only for the woman, but also the providers,” Anadani said. “So anything, any stroke-like symptoms like weakness, numbness, vision changes, speech difficulties, should be treated like stroke until proven otherwise.”

Editor’s Note: Anadani reports no relevant disclosures.

Anadani M, Hamoud L, Al Kasab S, et al. Pregnancy and Stroke: Insight From the Cosmos Database. Stroke. Published online February 2, 2026. 

Elgendy IY, Gad MM, Mahmoud AN, Keeley EC, Pepine CJ. Acute Stroke During Pregnancy and Puerperium. J Am Coll Cardiol. 2020;75(2):180-190. 

Anadani discusses a recent study highlighting the myriad contributing factors in the steadily increasing risk of maternal stroke across the country.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Stroke

On the HCPLive stroke page, resources on the topics of medical news and expert insight into CVA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on stroke medicine, and more.

Adrian Brown, PhD, NIHR Advanced Fellow and Associate Professor in Nutrition and Dietetics at University College London and programme co-lead of the MSc Dietetics (Pre-registration) course

Destigmatizing Obesity in Kidney Failure Patients Seeking Transplants, With Adrian Brown, PhD

barriers to equitable access in transplant care

 may open the door to a new future of clinical obesity management in this patient population.

This was the first systematic review to synthesize the perspectives of both clinicians and patients on obesity management in kidney failure before transplantation, and the findings underscored a disconnect between clinicians’ communication and patients' psychological well-being, especially when stigma was present.

“Enhancing communication is actually essential,” said Adrian Brown, PhD, NIHR Advanced Fellow and Associate Professor in Nutrition and Dietetics at University College London and programme co-lead of the MSc Dietetics (Pre-registration) course, in an interview with 

Clinicians should receive training to help them discuss weight sensitively, to guide weight bias and stigma, and to support patients in a way that makes them feel respected, and that the communication and the engagement are collaborative.”

Brown and colleagues conducted a mixed-methods systematic review, constructing 4 main themes from 738 participants from 7 studies investigating patients' and clinicians' perspectives on obesity management in kidney failure. These included:

Hungry and exhausted: The impact of dialysis on eating behaviour and activity (n = 339)

Weight stigma–lack of support, trust and open communication (n = 212)

Lack of resources as a barrier for weight loss (n = 339)

Who gets a transplant? Moving beyond BMI to improve equity in transplantation (n = 631).

In total, 4 studies included clinicians’ perspectives (n = 495), such as dieticians (n = 41), nephrologists (n = 438) and transplant surgeons (n = 12).

Hungry and exhausted: The impact of dialysis on eating behaviour and activity

Appearing in 6 papers, investigators identified diet and exercise as the most common weight loss interventions in patients with kidney failure.

From this study, investigators observed communication linguistics surrounding dietary advice included portion control, mindful eating and self-monitoring as the most common interventions for obesity management.

From a patient’s perspective, this guidance was hard to adhere to, given the “incompatibility” between this advice and the dietary/liquid restrictions, hunger, and exhaustion while going through dialysis. In fact, dialysis itself was often reported as a hindrance to weight loss based on its impact on eating behaviour, energy, and hunger, deterring intentional meal preparation and the stress and boredom patients expressed during treatment.

Building off of dialysis’s impact on energy related to diet, exhaustion was an obstacle for patients attempting to exercise, even though this was the second most common obesity management approach.

Weight stigma–lack of support, trust and open communication

This theme stood out as a measure of the communication barriers between patients and clinicians, specifically how instances of bias led to what patients described as inadequate support and advice, often leading them to feel responsibility and self-blame.

As study investigators observed, clinicians tended to tiptoe around conversations surrounding weight and obesity, not wishing to “embarrass” patients by initiating the topic. Dialysis facilities themselves were seen as a separate barrier, given the lack of privacy and public nature of treatment. Overall, clinicians either expressed an expectation for patients to bring obesity up for themselves, or a desire to focus on other clinical workload.

Investigators noted a few instances of clinicians' apparent bias and negative attitudes towards patients with obesity, and identified this stigma as a roadblock toward transplantation and a detriment to patients' psychological well-being.

Lack of resources as a barrier for weight loss

Brown and colleagues described this theme as resource-related barriers, including lack of time, limited obesity knowledge, and funding. Overall, these reduced the ability and motivation of the patient and clinician to address obesity.

Some patients viewed weight loss as time-consuming; others did not have an urgency to lose weight until reaching a more severe level of CKD. Notably, both patients and clinicians reported a lack of time and motivation to actively pursue or support weight loss.

According to Brown, many clinicians felt obesity management was outside the scope of their role, which led to gaps in care. Clinicians were unsure about their roles in addressing obesity in dialysis and identified the absence of obesity management guidelines as a key challenge.

Of note, barriers to food access, including cost and inaccessibility, were also identified as a major barrier to weight loss for patients with kidney failure.

Who gets a transplant? Moving beyond BMI to improve equity in transplantation

Lastly, from the findings, Brown and colleagues discovered 4 papers where clinicians considered obesity during transplant eligibility assessments. Overall, there was a lack of consensus on how to measure body composition or operationalize eligibility for kidney transplantation.

A majority of clinicians believed having a body mass index (BMI) ≥ 40 kg/m2 was a contraindication for kidney transplantation, with 50% suggesting a BMI of 40 kg/m2 was an appropriate limit, while others said 30–35 kg/m2. Otherwise, clinicians believed BMI limits excluded patients.

“There needs to be a shift to create a system that recognizes obesity as a medical condition in its own life, requiring coordinated care,” said Brown. “And this needs to be prioritized for transplant access, both for the patients and the clinicians, working towards getting better clinical outcomes and ultimately getting patients access to transplantation.”

Editor’s Note: Brown reports relevant disclosures with Novo Nordisk and Reset Health.

Oganesova Z, MacLaughlin HL, McCafferty K, et al. Patient and clinician perspectives on the management of obesity in kidney failure prior to kidney transplantation: a mixed-methods systematic review. eClinicalMedicine. 2026;91:103649. doi:

https://doi.org/10.1016/j.eclinm.2025.103649

Brown A. Barriers to Obesity Management in Kidney Failure Before Transplantation. HCPLive. Published February 24, 2026. Accessed February 26, 2026. 

https://www.hcplive.com/view/barriers-to-obesity-management-in-kidney-failure-before-transplantation

Brown discusses a destigmatised future of obesity management in patients with kidney failure. 


Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Chronic Kidney Disease

Bhatt discusses a recent study from GSK highlighting AREXVY’s efficacy in lowering major adverse cardiovascular events.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

RSV Vaccine Demonstrates Cardioprotective Effects, Reduces MACE and Hospitalizations, With Deepak Bhatt, MD, MPH

Abigail Brooks is an assistant managing editor for 

She joined MJH Life Sciences in August 2023 shortly after graduating from Monmouth University where she earned her BA in Communication with a concentration in Public Relations/Journalism and later an MA in Interactive Digital Media. She enjoys traveling, running, and reading books. She can be reached at abrooks@mjhlifesciences.com.

Ross Milner, MD, discusses rising vascular complexity, advanced imaging and AI, and the team-based strategies driving durable aortic and limb salvage outcomes.

Atherosclerotic Cardiovascular Disease

Expanding the Toolbox for Complex Aorta and Limb Salvage

Joselle Cook, MD, MBBS, is a hematologist and oncologist, specializing in Myeloma, Amyloid and Plasma cell disorders at the Mayo Clinic in Rochester Minnesota.

Panelist member explains new ASH guidelines aim to improve early diagnosis of AL amyloidosis with blood, urine, and biopsy testing.


Hematology

Key Insights on New ASH Guidelines for AL Amyloidosis, With Joselle Cook, MD

Manreet Kanwar, MD, outlines advances in heart failure care, rising medication complexity, and the need for integrated, patient-centered systems.

Heart Failure

The HCPLive heart failure page is a resource for medical news and expert insights on HF. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for heart disease, reduced and preserved ejection fraction, and more.

Comprehensive, Multidisciplinary Care for Complex Cardiac Disease

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

AAAAI 2026 showcases high-impact clinical trials and innovative sessions, 5 of which are highlighted below.



AAAAI Annual Meeting 2026 Preview: 5 Trials to Know

David Rubin, MD, discusses rapid advances in IBD care, new therapies, multidisciplinary models, and the push toward precision GI medicine.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Hepatology

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Expanding Clinical Reach in GI and Hepatology While Preserving Standards of Care

Gregg Pressman, MD, is a professor of medicine in the division of cardiology, Jefferson Einstein Philadelphia Hospital, Thomas Jefferson University.

Pressman discusses his recent study highlighting the interplay between right ventricular end-diastolic volume and ejection fraction and the left ventricle’s health.

Structural Heart Disease

Strategic Alliance Partnership

Low-Grade Diastolic Dysfunction Still Harms Left Ventricle Function, With Gregg Pressman, MD

Fernando Magro, MD, PhD, is head of clinical pharmacology at University Hospital São João.

4-year LUCENT data show mirikizumab reduces UC-related hospitalizations and surgeries, supporting durable remission and potential disease modification.

Ulcerative Colitis

Ulcerative Colitis condition center page, resources on the topics of medical news and expert insight into colitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on UC research, treatment, and drug development.

LUCENT: Durable UC Control With Mirikizumab Through 4 Years, With Fernando Magro, MD, PhD

In this interview, Neal Bhatia, MD, highlights several key points about treating psoriasis and obesity via ixekizumab and tirzepatide.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Discussing Promising New Findings on GLP-1 Use in Psoriasis Management, With Neal Bhatia, MD

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Parent company Eli Lilly has released full data from ACHIEVE-3, indicating superior weight loss and A1C reductions with orforglipron 12 mg and 36 mg.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Latest News

Tapinarof Cream 1% Improves Sleep in Atopic Dermatitis, With Druhan Howell, MD

CAFETERIA: Expanding Treatment Pathways for High-Threshold Peanut Allergy, with Scott Sicherer, MD

Nemolizumab Shows Long-Term Efficacy in Prurigo Nodularis for Up to 3 Years

Pregnancy-Related Maternal Stroke Increasing Across US, With Mohammad Anadani, MD

Destigmatizing Obesity in Kidney Failure Patients Seeking Transplants, With Adrian Brown, PhD